… efficacy, mechanisms of action, safety, and tolerability. … Flushing depends on the tolerance
and compromises the … after 12 weeks of treatment with the extended-release form of niacin (1–…

… factors including the intensity, tolerance, individual choice, price … not been a significant effect
with niacin monotherapy [117]. In … on the effects of extended-release niacin in women. Am J …

… -C in response to treatment, with a safe reduction of the CV … -risk patients who do not tolerate
daily doses of a specific statin [… about the effects of niacin monotherapy on major CV events […

… or in case of statin intolerance. We include the possible … patients on concomitant
extended-release niacin/laropiprant 2 g/… combination therapy compared with statin monotherapy …

… for patients who require additional or alternative non-statin treatment of hyperlipidemia. …
, which is a possible side effect of fibrate monotherapy. Niacin mainly exerts its effects via the …

… if RYR extract is safe during … intolerance, (2) patients with dyslipidemia ineligible for statin
therapy, and (3) patients with a strong preference for RYR extract over conventional treatment. …

… Niacin was the first drug approved to treat dyslipidemia. In … sustained release niacin and
extended-release niacin are once a … tolerate statin therapy one needs to use other drugs to treat …

… after pharmacological treatment or does not tolerate the drugs [14]. … Niacin extendedrelease/simvastatin
combination therapy … particles than atorvastatin monotherapy. Vasc Health Risk …

… after aggressive statin monotherapy in primary prevention … intolerance may occur in a
significant subset of statin-treated … Flushing occurs less frequently with extended-release niacin …

… statin intolerance, (2) patients with dyslipidemia ineligible for … or dyslipidemia found that
niacin monotherapy reduced the … use of extended-release niacin and laropiprant, and niacin is …